Skip to main content
SpringerLink
Log in

Lassen Sie Ihre Patienten wieder freier atmen!

Aktuelle Therapieoptionen bei der COPD

COPD-Management, a comprehensive review

  • FORTBILDUNG . ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Zusammenfassung

Die chronisch-obstruktive Lungenerkrankung (COPD) wurde lange Zeit als eine Erkrankung der Atemwege und der Lunge mit irreversiblen Veränderungen des Lungenparenchyms (Lungenemphysem) und einer nicht oder nur schwer behandelbaren Atemwegsobstruktion angesehen. Dieses Bild hat sich bis heute grundlegend geändert.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet. 2017;389:1931–40

    Article  PubMed  Google Scholar 

  2. Committee GE. Global initiative for chronic obstructive lung disease. www goldcopd com 2017

  3. Lopez AD, Murray CC. The global burden of diseases. Natur Med. 1998;4:1241–3

    Article  CAS  Google Scholar 

  4. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet. 1997;349:1269–76

    Article  CAS  PubMed  Google Scholar 

  5. Geldmacher H, Biller H, Herbst A et al. Die Prävalenz der chronisch-obstruktiven Lungenerkrankung (COPD) in Deutschland. Dtsch Med Wschr. 2008;133:2609–14

    Article  CAS  PubMed  Google Scholar 

  6. Gillissen A, Lommatzsch M, Prenzler A et al. Chronisch obstruktive Lungenerkrankung (COPD). In: Gillissen A, Welte T, Hrsg. Weißbuch Lunge 2014 Die Lunge und ihre Erkrankungen: Zur Lage und Zukunft der Pneumologie ind Deutschland. 1. Aufl. Herne: Frischtexte Verlag; 2014:47–57

    Google Scholar 

  7. Glaser S, Schaper C, Obst A et al. Impact of different definitions of airflow limitation on the prevalence of chronic obstructive pulmonary disease in the general population. Respiration. 2010;80:292–300

    Article  PubMed  Google Scholar 

  8. Varkey AB. Chronic obstructive pulmonary disease in women: exploring gender differences. Curr Opin Pulm Med. 2004;10:98–103

    Article  PubMed  Google Scholar 

  9. Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur Respir J. 2009;34:757–69

    Article  CAS  PubMed  Google Scholar 

  10. Beeh KM, Beier J. Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways disease. Adv Ther. 2009;26:691–9

    Article  CAS  PubMed  Google Scholar 

  11. Andrus MR, Loyed JV. Use of beta-adrenoceptor antagonists in older patients with chronic obstrucitve pulmonary disease and cardiovascular co-morbidity: safety issues. Drugs Aging. 2008;25:131–44

    Article  CAS  PubMed  Google Scholar 

  12. Rodrigo GJ, Nannini LJ, Rodriguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest 2008;133: 1079–87

    Article  CAS  PubMed  Google Scholar 

  13. Taylor MRG. Pharmacogenetics of the human beta-adrenergic receptors. Pharmacogenomics J. 2007;7:29–37

    Article  CAS  PubMed  Google Scholar 

  14. Brunson M, Bailey WC. Anticholinergics. In: Pauwels RA, Postma DS, Weiss ST, Hrsg. Lung biology in health and disease. 1. Aufl. New York: Marcel Dekker; 2005:353–82

    Google Scholar 

  15. Vogelmeier C, Hederer B, Glaab T et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364:1093–103

    Article  CAS  PubMed  Google Scholar 

  16. Hilleman DE, Malesker MA, Morrow LE et al. A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD. Int J COPD. 2009;4:253–63

    Article  CAS  Google Scholar 

  17. Kesten S, Celli BR, Decramer M et al. Tiotropium handiHaler in the treatment of COPD: a safety review. Int J Chron Obstruct Pulmon Dis. 2009;4:397–409

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Salpeter SR. Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events ? A synthesis of the available evidence. Drugs. 2009;69:2025–33

    Article  CAS  PubMed  Google Scholar 

  19. (ÄZQ) ÄZfQidM. Nationale Versorgungsleitlinie COPD. In: Bundesärztekammer (BÄK) AdWMFA, Bundesä eds; www.ersorgungsleitlinien.de. 1.8 ed; 2011:1–99

  20. Committee GEaS. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: National Institutes of Health, World Health Organization; 2017; www.ginasthma.org

  21. Wedzicha JA. Choice of bronchodilator therapy for patients with COPD. N Engl J Med. 2011;364:1167–8

    Article  CAS  PubMed  Google Scholar 

  22. Gillissen A, Kahler CM, Koczulla AR et al. Chronisch obstruktive Lungenerkrankung: So setzen Sie die aktualisierten GOLD-Empfehlungen um. MMW Fortschr Med. 2017;159(12):56–9

    Article  PubMed  Google Scholar 

  23. Gillissen A, Haidl P, Kohlhäufl M et al. The Pharmacological Treatment of Chronic Obstructive Pulmonary Disease. Dtsch Arztebl Int. 2016;113:311–6

    PubMed  PubMed Central  Google Scholar 

  24. Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J. 2015;45:525–37

    Article  CAS  PubMed  Google Scholar 

  25. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;3: CD010115

    Google Scholar 

  26. Battaglia S, Cardillo I, Lavorini F et al. Safety considerations of inhaled corticosteroids in the elderly. Drugs Aging. 2014;31:787–96

    Article  CAS  PubMed  Google Scholar 

  27. Subramanian, Ragulan, Jindal A et al. The Study of Efficacy, Tolerability and Safety of Theophylline Given Along with Formoterol Plus Budesonide in COPD. J Clin Diagn Res. 2015;9:OC10–3

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Chen CY, Yang KY, Lee YC et al. Effect of oral aminophylline on pulmonary function improvement and tolerability in different age groups of COPD patients. Chest. 2005;128:2088–92

    Article  CAS  PubMed  Google Scholar 

  29. Rabe KF, Dent G, Magnussen H. Pharmakodynamik des Theophyllins. In: Ukena D, Keller A, Nolte D, Hrsg. Theophyllin - Controller and Reliever bei Asthma und COPD. München-Deisenhofen: Dustri-Verlag Dr. Karl Feistle; 1999:1–39

    Google Scholar 

  30. Gillissen A. Bewertung der Theophyllin-Therapie beim Asthma bronchiale. MMW Fortschr Med. 1997;139

  31. Fexer J, Donnachie E, Schneider A et al. The effects of theophylline on hospital admissions and exacerbations in COPD patients: audit data from the Bavarian disease management program. Dtsch Arztebl Int. 2014;111:293–300

    PubMed  PubMed Central  Google Scholar 

  32. Martinez FJ, Calverley PM, Goehring UM et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385:857–66

    Article  CAS  PubMed  Google Scholar 

  33. Wedzicha JA, Rabe KF, Martinez FJ et al. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest. 2013;143:1302–11

    Article  CAS  PubMed  Google Scholar 

  34. Fabbri LM, Calverley PMA, Izquierdo-Alonso JL et al. Roflumilast in moderate to severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised trials. Lancet. 2009;374:695–703

    Article  CAS  PubMed  Google Scholar 

  35. Rabe KF, Calverley PMA, Martinez FJ et al. Effect of roflumilast in patients with severe COPD and a history of hospitalisation. Eur Respir J. 2017;50

  36. Worth H, Buhl R, Criee CP et al. The ‚real-life‘ COPD patient in Germany: The DACCORD study. Respir Med. 2016;111:64–71

    Article  PubMed  Google Scholar 

  37. Simeone JC, Luthra R, Kaila S et al. Initiation of triple therapy maintenance treatment among patients with COPD in the US. Int J Chron Obstruct Pulmon Dis. 2017;12:73–83

    Article  PubMed  Google Scholar 

  38. Montuschi P, Malerba M, Macis G et al. Triple inhaled therapy for chronic obstructive pulmonary disease. Drug Discov Today. 2016;21:1820–7

    Article  CAS  PubMed  Google Scholar 

  39. Wedzicha JA, Singh D, Vestbo J et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir Med. 2014;108:1153–62

    Article  CAS  PubMed  Google Scholar 

  40. Pascoe S, Locantore N, Dransfield MT et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3:435–42

    Article  CAS  PubMed  Google Scholar 

  41. Pascoe SJ, Lipson DA, Locantore N et al. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Respir J. 2016;48:320–30

    Article  CAS  PubMed  Google Scholar 

  42. Singh D, Papi A, Corradi M et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388:963–73

    Article  CAS  PubMed  Google Scholar 

  43. Lim HS, Choi SM, Lee J et al. Responsiveness to inhaled corticosteroid treatment in patients with asthma-chronic obstructive pulmonary disease overlap syndrome. Ann Allergy Asthma Immunol. 2014;113:652–7

    Article  CAS  PubMed  Google Scholar 

  44. Gibson PG, McDonald VM. Asthma-COPD overlap 2015: now we are six. Thorax 2015, DOI: thoraxjnl-2014-206740 [pii];10.1136/thoraxjnl-2014-206740 [doi]

  45. Watz H, Tetzlaff K, Wouters EF et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016, DOI: 10.1016/S2213-2600(16)00100-4

  46. Voshaar T, Idzko M, Münks-Lederer C et al. Einsatz inhalativer Mono- und Kombinationstherapien. Dtsch Arztebl. 2016;113(24):4

    Google Scholar 

  47. Gillissen A. Tatsächliche Güte der Asthmaeinstellung und Möglichkeiten der zukünftigen Therapieoptimierung. Pneumologie. 2015;69:36–47

    Article  CAS  PubMed  Google Scholar 

  48. Gillissen A. Patientenpräferenz von Inhalern. Pneumologie. 2015;68:727–36

    Google Scholar 

  49. Voshaar T, App EM, Berdel D et al. Empfehlungen für die Auswahl von Inhalationssystemen zur Medikamentenverabreichung. Pneumologie. 2002;55:579–86

    Article  Google Scholar 

  50. Worth H, Schacher C, Dethlefsen U. Concomitant therapy with cineole (eucalyptole) reduces exacerbations in COPD: a placebo-controlled double-blind trial. Resp Research 2009;10:70–2; https://doi.org/10.1186/1465-9921-1110-1169

    Article  Google Scholar 

  51. Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2003;2:CD001287

    Google Scholar 

  52. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ. 2001;322:1–6

    Article  Google Scholar 

  53. Jund R, Mondigler M, Stammer H et al. Herbal drug BNO 1016 is safe and effective in the treatment of acute viral rhinosinusitis. Acta Otolaryngol. 2015;135:42–50

    Article  PubMed  PubMed Central  Google Scholar 

  54. Albert RK, Connett J, Bailey WC et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689–8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Marciniuk DD, Hernandez P, Balter M et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2012;19:109–16

    Article  PubMed  PubMed Central  Google Scholar 

  56. Rahaghi FF, Miravitlles M. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence. Respir Res. 2017;18:105

    Article  PubMed  PubMed Central  Google Scholar 

  57. Bernhard N, Bals R, Fahndrich S. Alpha-1-Antitrypsinmangel - was gibt es Neues ? Dtsch Med Wochenschr. 2016;141:1467–9

    Article  PubMed  Google Scholar 

  58. Chapman KR, Burdon JG, Piitulainen E et al. Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:360–8

    Article  CAS  PubMed  Google Scholar 

  59. Greulich T. Alpha-1-Antitrypsin Deficiency: Disease Management and Learning from Studies. COPD. 2017;14:8–11

    Article  Google Scholar 

  60. Greulich T, Nell C, Hohmann D et al. The prevalence of diagnosed alpha1-antitrypsin deficiency and its comorbidities: results from a large population-based database. Eur Respir J. 2017;49:pii 600154

    Article  Google Scholar 

  61. Greulich T, Averyanov A, Borsa L et al. European screening for alpha1 -antitrypsin deficiency in subjects with lung disease. Clin Respir J. 2017;11:90–7

    Article  CAS  PubMed  Google Scholar 

  62. Andreas S, Batra A, Behr J et al. Tabakentwöhnung bei COPD. S3 Leitlinie herausgegeben von der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin. Pneumologie. 2008;62:255–72

    Article  CAS  PubMed  Google Scholar 

  63. Makris D, Moschandreas J, Damianaki A et al. Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. Respir Med. 2007;101:1305–12

    Article  CAS  PubMed  Google Scholar 

  64. Anthonisen NR, Skeans M, Wise RA et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142:233–9

    Article  PubMed  Google Scholar 

  65. Scanlon PD, Connett JE, Waller LA et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med. 2000;161:381–90

    Article  CAS  Google Scholar 

  66. Tremblay M, Gervais A, Lacroix C et al. Physicians taking action against smoking: an intervention program to optimize smoking cessation counselling by Montrealgeneral practitioners. CMAJ 2001;165:601–7

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Boeselt T, Nell C, Lutteken L et al. Benefits of High-Intensity Exercise Training to Patients with Chronic Obstructive Pulmonary Disease: A Controlled Study. Respiration. 2017;93:301–10

    Article  CAS  PubMed  Google Scholar 

  68. Spielmanns M, Meier A, Winkler A et al. Eine pneumologische Rehabilitation nach akuter Exazerbation der COPD senkt die Rate erneuter Exazerbationen. Dtsch Med Wochenschr. 2017;142:e10–19

    Article  PubMed  Google Scholar 

  69. Boeselt T, Spielmanns M, Nell C et al. Validity and Usability of Physical Activity Monitoring in Patients with Chronic Obstructive Pulmonary Disease (COPD). PLoS One 2016;11:e0157229

    Article  PubMed  PubMed Central  Google Scholar 

  70. Vogelmeier C, Buhl R, Criee C-P et al. Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD). Pneumologie. 2007;61:e1–40

    Article  CAS  PubMed  Google Scholar 

  71. Petro W, Buhr-Schinner H, Taube K et al. Rehabilitation bei COPD. Pneumologie 2007;61:384–92

    Article  CAS  PubMed  Google Scholar 

  72. Wittmann M, Spohn S, Schultz K et al. COPD-Schulung im Rahmen der stationären Rehabilitation verbessert Lebensqualität und Morbidität. Pneumologie. 2007;61:636–42

    Article  CAS  PubMed  Google Scholar 

  73. Gerardi D, ZuWallack R. Non-pulmonary factors affecting survival in patients completing pulmonary rehabilitation. Monaldi Arch Chest Dis. 2001;56:331–5

    CAS  PubMed  Google Scholar 

  74. Magnussen H, Kirsten A-M, Köhler D et al. Leitlinien zur Langzeit-Sauerstofftherapie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V. Pneumologie. 2008;62:748–56

    Article  CAS  PubMed  Google Scholar 

  75. Long-Term Oxygen Treatment Trial Research G, Albert RK, Au DH et al. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med. 2016;375:1617–27

    Article  Google Scholar 

  76. Gorecka D, Gorzelak K, Sliwinski P et al. Effect of long term oxygen therapy on survival in patients with chronic obstrucitve airway disease. Thorax. 1997;52:674–9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Windisch W, Brambring J, Budweiser S et al. Nichtinvasive und invasive Beatmung als Therapie der chronischen respiratorischen Insuffizienz. Pneumologie. 2010;64:207–40

    Article  CAS  PubMed  Google Scholar 

  78. Randerath W, Lorenz J, Windisch W et al. Betreuung von Patienten mit maschineller Beatmung unter häuslichen und heimpflegerischen Bedingungen. Pneumologie. 2008;62:305–8

    Article  CAS  PubMed  Google Scholar 

  79. Group NETR, National. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348:2059–73

    Article  Google Scholar 

  80. Strange C, Herth FJ, Kovitz KL et al. Design of the endobronchial valve for emphysema palliation trial (VENT): a non-surgical method of lung volume reduction. BMC Pulmonary Medicine. 2007;7:10

    Article  PubMed  PubMed Central  Google Scholar 

  81. Shah PL, Herth FJ, van Geffen WH et al. Lung volume reduction for emphysema. Lancet. Respir Med. 2017;5:147–56

    Article  PubMed  Google Scholar 

  82. Gompelmann D, Eberhardt R, Herth F. Endoscopic volume reduction in COPD- a critical review. Dtsch Arztebl Int. 2014;111:827–33

    PubMed  PubMed Central  Google Scholar 

  83. McKenna JRJ. Endobronchial valves for the treatment of emphysema. Semin Thorac Cardiovasc Surg. 2008;20:285–9

    Article  PubMed  Google Scholar 

  84. Sciurba FC, Criner GJ, Strange C et al. Effect of Endobronchial Coils vs Usual Care on Exercise Tolerance in Patients With Severe Emphysema: The RENEW Randomized Clinical Trial. JAMA. 2016;315: 2178–89

    Article  CAS  PubMed  Google Scholar 

  85. Shah PL, Gompelmann D, Valipour A et al. Thermal vapour ablation to reduce segmental volume in patients with severe emphysema: STEP-UP 12 month results. Lancet Respir Med. 2016;4:e44–5

    Article  PubMed  Google Scholar 

  86. Herth FJ, Valipour A, Shah PL et al. Segmental volume reduction using thermal vapour ablation in patients with severe emphysema: 6-month results of the multicentre, parallel-group, open-label, randomised controlled STEP-UP trial. Lancet Respir Med. 2016;4:185–93

    Article  PubMed  Google Scholar 

  87. Gompelmann D, Eberhardt R, Herth FJ. Technology update: bronchoscopic thermal vapor ablation for managing severe emphysema. Med Devices (Auckl). 2014;7:335–41

    Article  Google Scholar 

  88. Budweiser S, Jörres RA, Pfeifer M. Noninvasive home ventilation for chronic obstructive pulmonary disease: indications, utility and outcome. Curr Opin Pulm Med. 2008;14:128–34

    Article  PubMed  Google Scholar 

  89. Ambrosino N, Vagheggini G. Noninvasive positive pressure ventilation in the acute care setting: where are we? Eur Respir J 2008;31:874–86

    Article  CAS  PubMed  Google Scholar 

  90. Keenan SP, Gregor J, Sibbald WJ et al. Noninvasive positive pressure ventilation in the setting of severe, acute exacerbations of chronic obstructive pulmonary disease: more effective and less expensive. Crit Care Med. 2000;28:2094–102

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kreiskliniken Reutlingen / Ermstalklinik, Med. Klinik III Innere Medizin/Pneumologie, Stuttgarter-Str. 100, D.72574, Reutlingen-Bad Urach, Deutschland

    A. Gillissen M.Sc.

  2. Klinik für Pneumologie, Beatmungsmedizin und Allergologie, Wangen im Allgäu, Deutschland

    Christian M. Kähler

  3. Klinik für Pneumologie, Universitätsklinikum Gießen und Marburg, Marburg, Deutschland

    A. Rembert Koczulla

  4. Lungenzentrum Ulm, Ulm, Deutschland

    Rüdiger Sauer

  5. Universitätsklinikum Hamburg-Eppendorf, Hamburg-Eppendorf, Deutschland

    Maria Paparoupa

Authors
  1. A. Gillissen M.Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian M. Kähler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Rembert Koczulla
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rüdiger Sauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria Paparoupa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Gillissen M.Sc..

Additional information

This article is part of a supplement not sponsored by the industry.

INTERESSENKONFLIKTE

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Sie legen folgende potenzielle Interessenkonflikte offen: Prof. Gillissen: Beratungs- und/oder Vortragstätigkeit bzw. Kongressreiseunterstützung für die Firmen Berlin-Chemie, Chiesi, Novartis, Pohl-Boskamp und AstraZeneca; Prof. Koczulla: Vortragstätigkeit für die Firmen Boehringer-Ingelheim, Astra Zeneca, Novartis, Grifols, CSCSL, Roche, Teva, Berlin-Chemie, Chiesi und Novotec; Prof. Kähler: Zusammenarbeit in Studien, Beratungs- und Vortragstätigkeit und Bezug von Forschungsgeldern durch die Firmen AstraZeneca, Chiesi, Boehringer-Ingelheim, GSK, Novartis und Mundipharma. Herr Dr. Sauer und Frau Dr. Paparoupa: keine.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags von zwei unabhängigen Gutachtern geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gillissen, A., Kähler, C.M., Koczulla, A.R. et al. Aktuelle Therapieoptionen bei der COPD. MMW - Fortschritte der Medizin 159 (Suppl 3), 32–43 (2017). https://doi.org/10.1007/s15006-017-9594-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-017-9594-5

Keywords

Search

Navigation